CD73 expression in lymph node metastases in patients with head and neck cancer

• Published in: Acta oto-laryngologica 2018-02, Vol.138 (2), p.180-184
• Main Authors: Mandapathil, Magis, Boduc, Mehtap, Netzer, Christoph, Güldner, Christian, Roessler, Marion, Wallicek-Dworschak, Ute, Jahns, Evelyn, Stuck, Boris
• Format: Article
• Language: English
• Subjects: CD73; ectonucleotidases; Head and neck cancer; lymph node metastases
• ISSN: 0001-6489; 1651-2251
• DOI: 10.1080/00016489.2017.1378436

Introduction: CD73 is an enzyme crucial in the metabolism of immunosuppressive adenosine. In cancer, it has various functions including tumor growth and metastases. Squamous cell carcinoma of the head and neck has an overall poor prognosis, also due to early spread of metastatic cells. Materials and methods: Tumor and lymph node specimens of 65 patients with HNSCC were subjected to immunohistochemical and H-score analysis of CD73 expression. Demographics, diagnoses, histopathology and subsequent outcome were analyzed. Results: The primary cancer was squamous cell carcinoma in all patients (male/female 55:10) with the following locations: oral cavity n:16, oropharynx n:28, hypopharynx n:11 and larynx n:10. H-score for CD73 expression in the primary lesion and metastatic lymph nodes was significantly higher in advanced compared to early stages with no significant differences among tumor locations. High CD73 expression was associated with reduced overall survival rates at a mean follow-up of 83.4 months (6-204 months). Conclusions: CD73 expression in HNSCC correlated positively with tumor stage and was associated with poor prognosis. Therefore, CD73 expression in primary lesions and regional metastases appears to predict HNSCC patients at high risk of all tumor sites. Therapeutic approaches targeting CD73 might seem promising for this patient population.